Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Papp

Showing results (21-30 of 137) with videos related to

Pageof 14
Sort By:
Journal of Cutaneous Medicine and Surgery|July 31, 2015
A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis VulgarisVictoria Taraska, Raj Tuppal, Martin Olesen, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 14, 2009
Immunosuppressive therapy in dermatology and PMLWolfram Sterry, Martine Bagot, Carlos Ferrandiz, et al.
Advances in Therapy|March 6, 2025
A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque PsoriasisKim Papp, Sigrid Balser, Katrin Nopora, et al.
The Journal of Dermatological Treatment|February 6, 2010
Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasisYves Poulin, Kim Papp, Robert Bissonnette, et al.
Journal of Cutaneous Medicine and Surgery|November 19, 2009
A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patientsNorman Wasel, Yves Poulin, Robin Andrew, et al.
Journal of the American Academy of Dermatology|July 15, 2011
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEALKenneth Gordon, Kim Papp, Yves Poulin, et al.
Journal of Cutaneous Medicine and Surgery|May 22, 2016
A Review of Psoriasis, Therapies, and SuicideMelinda Gooderham, Jennifer Gavino-Velasco, Cole Clifford, et al.
Journal of the American Academy of Dermatology|January 30, 2024
Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label studyKim Papp, Vimal H Prajapati, Catherine Maari, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trialGerald G Krueger, Boni Elewski, Kim Papp, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE studyGordon Searles, Robert Bissonnette, Ian Landells, et al.
Pageof 14

Showing results (21-30 of 137) with videos related to

Sort By:
Pageof 14
Journal of Cutaneous Medicine and Surgery|July 31, 2015
A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis VulgarisVictoria Taraska, Raj Tuppal, Martin Olesen, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 14, 2009
Immunosuppressive therapy in dermatology and PMLWolfram Sterry, Martine Bagot, Carlos Ferrandiz, et al.
Advances in Therapy|March 6, 2025
A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque PsoriasisKim Papp, Sigrid Balser, Katrin Nopora, et al.
The Journal of Dermatological Treatment|February 6, 2010
Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasisYves Poulin, Kim Papp, Robert Bissonnette, et al.
Journal of Cutaneous Medicine and Surgery|November 19, 2009
A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patientsNorman Wasel, Yves Poulin, Robin Andrew, et al.
Journal of the American Academy of Dermatology|July 15, 2011
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEALKenneth Gordon, Kim Papp, Yves Poulin, et al.
Journal of Cutaneous Medicine and Surgery|May 22, 2016
A Review of Psoriasis, Therapies, and SuicideMelinda Gooderham, Jennifer Gavino-Velasco, Cole Clifford, et al.
Journal of the American Academy of Dermatology|January 30, 2024
Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label studyKim Papp, Vimal H Prajapati, Catherine Maari, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trialGerald G Krueger, Boni Elewski, Kim Papp, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE studyGordon Searles, Robert Bissonnette, Ian Landells, et al.
Pageof 14